Axatilimab (anti-CSF-1R antibody for advanced MPN/CMML)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-13 — Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia: Phase Ib/II trial (trial-early) evaluating axatilimab monotherapy or in combination with azacitidine for safety and efficacy in advanced-phase MPN, MPN/MDS overlap, and high-risk CMML — establishes the first clinical evaluation of CSF-1R blockade (targeting monocyte/macrophage trafficking) in these indications. (novelty: 4)
Open questions
Related
Contributing findings
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
13-mar-2026
novelty 4
per-area 5
introduces